Invention Grant
- Patent Title: Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
-
Application No.: US16422256Application Date: 2019-05-24
-
Publication No.: US11474112B2Publication Date: 2022-10-18
- Inventor: Robert Arch , Jun Zhang , Michelle Mader , Tetsuya Ishino , Joel Bard , William Finlay , Orla Cunningham , Ciara Reilly , Peter Brams , Brigitte Devaux , Haichun Huang , Karla Henning
- Applicant: Pfizer Inc. , Bristol-Myers Squibb Company
- Applicant Address: US NY New York; US NJ Princeton
- Assignee: Pfizer Inc.,Bristol-Myers Squibb Company
- Current Assignee: Pfizer Inc.,Bristol-Myers Squibb Company
- Current Assignee Address: US NY New York; US NJ Princeton
- Agency: Scully, Scott, Murphy & Presser, P.C.
- Main IPC: G01N33/68
- IPC: G01N33/68 ; C07K16/28
Abstract:
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Public/Granted literature
- US20190331694A1 TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF Public/Granted day:2019-10-31
Information query
IPC分类:
